19
May
Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild and moderate COVID-19 infection Hyderabad (Telangana) [India], May 19: Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced. Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed…
